Novartis names once-yearly zoledronic acid Aclasta
Executive Summary
Aclasta will be the trade name for Novartis' once-yearly I.V. infusion formulation of zoledronic acid for treatment of Paget's disease. The priority review date on the Aclasta NDA is in March, the company said. Novartis anticipates a 2007 filing of Aclasta in treatment of osteoporosis (1"The Pink Sheet" Nov. 24, 2003, p. 29). Novartis also markets zoledronic acid under the trade name Zometa for treatment of prostate cancer...
You may also be interested in...
Zometa, Aredia May Have Different Jaw Osteonecrosis Risk Profiles
Further study of jaw osteonecrosis risk may differentiate Novartis' bisphosphonates Zometa and Aredia, FDA Division of Oncology Drug Products Director Richard Pazdur suggested
Novartis R&D Portfolio Grows 44% Since 2000; Half Of Projects Are NMEs
Novartis' clinical R&D portfolio has grown 44% over the last four years, with new molecular entities representing about half the drugs in development, Global Pharma Development Head Joerg Reinhardt, PhD, said Nov. 19 during Novartis' R&D day in New York
Finance Watch: A Summer Slowdown? Not For Venture Capital Mega-Rounds
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.